Morphine for Neonatal Abstinence Syndrome

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Neonatal Abstinence SyndromeClonidine - Drug
Eligibility
12 - 7
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether clonidine is an effective treatment for drug withdrawal in neonates. The hypothesis is that it will be effective.

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: 2 years of life

2 years of life
Bayley Scales of Infant and Toddler Development Third Edition
60 days
Duration of treatment
Week 6
Neurobehavioral Performance Summary Scores from the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Morphine
1 of 2
Clonidine
1 of 2

Active Control

200 Total Participants · 2 Treatment Groups

Primary Treatment: Morphine · No Placebo Group · Phase 3

Morphine
Drug
ActiveComparator Group · 1 Intervention: Morphine · Intervention Types: Drug
Clonidine
Drug
ActiveComparator Group · 1 Intervention: Clonidine · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years of life

Who is running the clinical trial?

Henrietta BadaLead Sponsor
1 Previous Clinical Trials
31 Total Patients Enrolled
1 Trials studying Neonatal Abstinence Syndrome
31 Patients Enrolled for Neonatal Abstinence Syndrome
National Institute on Drug Abuse (NIDA)NIH
2,245 Previous Clinical Trials
5,619,200 Total Patients Enrolled
12 Trials studying Neonatal Abstinence Syndrome
1,291 Patients Enrolled for Neonatal Abstinence Syndrome

Eligibility Criteria

Age 12 - 7 · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: